PURCHASE, NY, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Teladoc Health Inc. (NYSE: TDOC), the global leader in whole-person virtual care, announced that it will release third quarter 2024 results on Wednesday, October 30, 2024, after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day.
Conference Call Details
The conference call can be accessed by dialing 1-833-470-1428 for U.S. participants and using the access code # 781291. For international participants, please visit the following link for global dial-in numbers: https://www.netroadshow.com/events/global-numbers?confId=72270. A live audio webcast will also be available online at https://ir.teladoc.com/news-and-events/events-and-presentations/.
A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.
About Teladoc Health
Teladoc Health empowers all people everywhere to live their healthiest lives by transforming the healthcare experience. As the world leader in whole-person virtual care, Teladoc Health uses proprietary health signals and personalized interactions to drive better health outcomes across the full continuum of care, at every stage in a person’s health journey. Teladoc Health leverages more than two decades of expertise and data-driven insights to meet the growing virtual care needs of consumers and healthcare professionals. For more information, please visit www.teladochealth.com.
Investors:
Michael Minchak
This email address is being protected from spambots. You need JavaScript enabled to view it.
617-444-9612
| Last Trade: | US$9.00 |
| Daily Change: | 0.14 1.58 |
| Daily Volume: | 13,140,827 |
| Market Cap: | US$1.540B |
October 30, 2024 July 31, 2024 July 16, 2024 June 10, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
